Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Former Pfizer antibody reduces cardio risk marker in ph. 2
Pacibekitug, an antibody Tourmaline licensed from Pfizer in 2022, reduced levels of C-reactive protein in patients with chronic kidney disease.
Darren Incorvaia
May 20, 2025 7:30am
Atsena gene therapy hits safety goals, closes retinal splits
May 19, 2025 12:59pm
Apnimed eyes FDA sleep apnea submission after positive results
May 19, 2025 6:00am
J&J gene therapy fails ph. 3 rare eye disease trial
May 5, 2025 11:33am
Immunic MS asset misses primary goal of midstage trial
Apr 30, 2025 3:05pm
Fecal transplants alleviate fibromyalgia pain in small trial
Apr 28, 2025 7:30am
